The current epidemiology and clinical decisions surrounding acute respiratory infections

Trends in Molecular Medicine

Volumn 20, Issue 10, 2014, Pages 579-588

  Zaas, Aimee K ^a   Garner, Bronwen H ^a   Tsalik, Ephraim L ^a,b   Burke, Thomas ^a   Woods, Christopher W ^a,b   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Genomics; Host pathogen interaction; Viral respiratory infection

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

BACTERIAL INFECTION; BACTERIUM EXAMINATION; CLINICAL DECISION MAKING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HUMAN; IMMUNE RESPONSE; METABOLOMICS; NONHUMAN; PROTEOMICS; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS EXAMINATION; VIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; MICROBIOLOGY; MOLECULAR DIAGNOSIS; PROCEDURES; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

BIOLOGICAL MARKERS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMANS; METABOLOMICS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEOMICS; RESPIRATORY TRACT INFECTIONS;

EID: 84908138538     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.08.001     Document Type: Review

References (110)

1. Hong C.Y., et al. Acute respiratory symptoms in adults in general practice. Fam. Pract. 2004, 21:317-323.
2. Johnstone J., et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008, 134:1141-1148.
3. Cantrell R., et al. Antibiotic prescribing in ambulatory care settings for adults with colds, upper respiratory tract infections, and bronchitis. Clin. Ther. 2002, 24:170-182.
4. Shapiro D.J., et al. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J. Antimicrob. Chemother. 2014, 69:234-240.
5. Angus D., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
6. Dowell S.F., Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am. Fam. Physician 1997, 55:1647-1654.
7. Kunin C.M. Resistance to antimicrobial drugs: a worldwide calamity. Ann. Intern. Med. 1993, 118:557-561.
8. Neu H.C. The crisis in antibiotic resistance. Science 1992, 257:1064-1073.
9. Cohen M.L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992, 257:1050-1055.
10. Coenen S., et al. Appropriate international measures for outpatient antibiotic prescribing and consumption: recommendations from a national data comparison of different measures. J. Antimicrob. Chemother. 2014, 69:529-534.
11. Evans A., et al. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002, 359:1648-1654.
12. Hirschmann J. Antibiotics for common respiratory tract infections in adults. Arch. Intern. Med. 2002, 162:256-264.
13. Anevlavis S., et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J. Infect. 2009, 59:83-89.
14. van der Eerden M.M., et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24:241-249.
15. Spuesens E.B., et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013, 10:e1001444.
16. Sutter D.E., et al. Performance of five FDA-approved rapid antigen tests in the detection of 2009 H1N1 influenza A virus. J. Med. Virol. 2012, 84:1699-1702.
17. Anderson T.P., et al. Comparison of four multiplex PCR assays for the detection of viral pathogens in respiratory specimens. J. Virol. Methods 2013, 191:118-121.
18. Dabisch-Ruthe M., et al. Comparison of three multiplex PCR assays for the detection of respiratory viral infections: evaluation of xTAG respiratory virus panel fast assay, RespiFinder 19 assay and RespiFinder SMART 22 assay. BMC Infect. Dis. 2012, 12:163.
19. Kim H., et al. Comparison of two multiplex PCR assays for the detection of respiratory viral infections. Clin. Respir. J. 2013, 10.1111/crj.12083.
20. Popowitch E.B., et al. Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses. J. Clin. Microbiol. 2013, 51:1528-1533.
21. Jansen R.R., et al. Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J. Clin. Microbiol. 2011, 49:2631-2636.
22. Waugh T.R. The blood sedimentation test; its history, technique, nature and clinical application. Can. Med. Assoc. J. 1923, 13:604-608.
23. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus. J. Exp. Med. 1930, 52:561-571.
24. Tsalik E.L., Woods C.W. Sepsis redefined: the search for surrogate markers. Int. J. Antimicrob. Agents 2009, 34(Suppl. 4):S16-S20.
25. Assicot M., et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
26. Muller B., et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J. Clin. Endocrinol. Metab. 2001, 86:396-404.
27. Moyer M.W. New biomarkers sought for improving sepsis management and care. Nat. Med. 2012, 18:999.
28. Wacker C., et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect. Dis. 2013, 13:426-435.
29. Dandona P., et al. Procalcitonin increase after endotoxin injection in normal subjects. J. Clin. Endocrinol. Metab. 1994, 79:1605-1608.
30. Schuetz P., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst. Rev. 2012, 9:CD007498.
31. West M. Bayesian factor regression models in the 'large p, small n' paradigm. Bayesian Stat. 2003, 7:723-732.
32. Carvalho C.M., et al. High-dimensional sparse factor modeling: applications in gene expression genomics. J. Am. Stat. Assoc. 2008, 103:1438-1456.
33. Chen M., et al. Detection of viruses via statistical gene expression analysis. IEEE Trans. Biomed. Eng. 2011, 58:468-479.
34. Wu Y., Liu Y. Functional robust support vector machines for sparse and irregular longitudinal data. J. Comput. Graph. Stat. 2013, 22:379-395.
35. Witten D.M., et al. A penalized matrix decomposition, with applications to sparse principal components and canonical correlation analysis. Biostatistics 2009, 10:515-534.
36. Chaussabel D., Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat. Rev. Immunol. 2014, 14:271-280.
37. Pankla R., et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol. 2009, 10:R127.
38. Law G.L., et al. Systems virology: host-directed approaches to viral pathogenesis and drug targeting. Nat. Rev. Microbiol. 2013, 11:455-466.
39. Korth M.J., et al. Systems approaches to influenza-virus host interactions and the pathogenesis of highly virulent and pandemic viruses. Semin. Immunol. 2013, 25:228-239.
40. Vargas J., et al. Use of the Corus(R) CAD Gene Expression Test for assessment of obstructive coronary artery disease likelihood in symptomatic non-diabetic patients. PLoS Curr. 2013, 5.
41. Meadows S.K., et al. Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS ONE 2008, 3:e1912.
42. Jenner R.G., Young R.A. Insights into host responses against pathogens from transcriptional profiling. Nat. Rev. Microbiol. 2005, 3:281-294.
43. Boldrick J.C., et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:972-977.
44. Feezor R.J., et al. Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect. Immun. 2003, 71:5803-5813.
45. Fjaerli H.O., et al. Whole blood gene expression in infants with respiratory syncytial virus bronchiolitis. BMC Infect. Dis. 2006, 6:175.
46. Ramilo O., et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 2007, 109:2066-2077.
47. Huang Q., et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001, 294:870-875.
48. Cortez K.J., et al. Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus. Infect. Immun. 2006, 74:2353-2365.
49. Zaas A.K., et al. Blood gene expression signatures predict invasive candidiasis. Sci. Transl. Med. 2010, 2:21ra17.
50. Zaas A.K., et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 2009, 6:207-217.
51. Peng B., et al. An integrative framework for Bayesian variable selection with informative priors for identifying genes and pathways. PLoS ONE 2013, 8:e67672.
52. Lytkin N.I., et al. Expanding the understanding of biases in development of clinical-grade molecular signatures: a case study in acute respiratory viral infections. PLoS ONE 2011, 6:e20662.
53. Woods C.W., et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS ONE 2013, 8:e52198.
54. Huang Y., et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet. 2011, 7:e1002234.
55. Mejias A., et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med. 2013, 10:e1001549.
56. Chang J.T., Nevins J.R. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006, 22:2926-2933.
57. Dennis G., et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4:R60.
58. Carin L., et al. High-dimensional longitudinal genomic data: an analysis used for monitoring viral infections. IEEE Signal Process. Mag. 2012, 29:108-123.
59. Cox J., Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 2011, 80:273-299.
60. Schulze W.X., Usadel B. Quantitation in mass-spectrometry-based proteomics. Annu. Rev. Plant Biol. 2010, 61:491-516.
61. Lam Y.W., et al. Proteomics analysis of the nucleolus in adenovirus-infected cells. Mol. Cell. Proteomics 2010, 9:117-130.
62. Munday D.C., et al. Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus subgroup B using SILAC coupled to LC-MS/MS. Proteomics 2010, 10:4320-4334.
63. Kroeker A.L., et al. Response of primary human airway epithelial cells to influenza infection: a quantitative proteomic study. J. Proteome Res. 2012, 11:4132-4146.
64. Emmott E., et al. Quantitative proteomics using SILAC coupled to LC-MS/MS reveals changes in the nucleolar proteome in influenza A virus-infected cells. J. Proteome Res. 2010, 9:5335-5345.
65. Popova T.G., et al. Reverse-phase phosphoproteome analysis of signaling pathways induced by Rift valley fever virus in human small airway epithelial cells. PLoS ONE 2010, 5:e13805.
66. Henao R., et al. Latent protein trees. Ann. Appl. Stat. 2013, 7:691-713.
67. Ritter J.B., et al. Metabolic effects of influenza virus infection in cultured animal cells: intra- and extracellular metabolite profiling. BMC Syst. Biol. 2010, 4:61.
68. Lin S., et al. GC/MS-based metabolomics reveals fatty acid biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus. Talanta 2010, 83:262-268.
69. Tam V.C., et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 2013, 154:213-227.
70. Gilad S., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3:e3148.
71. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
72. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
73. Stark A., et al. Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature 2007, 450:219-232.
74. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3507-3512.
75. Volinia S., Croce C.M. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:7413-7417.
76. Haj-Ahmad T.A., et al. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J. Cancer 2014, 5:182-191.
77. Zhang J.X., et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013, 14:1295-1306.
78. Janssen H.L., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
79. Zhou A., et al. Interplay between microRNAs and host pathogen recognition receptors (PRRs) signaling pathways in response to viral infection. Virus Res. 2014, 184C:1-6.
80. Cui L., et al. Identification of microRNAs involved in the host response to enterovirus 71 infection by a deep sequencing approach. J. Biomed. Biotechnol. 2010, 2010:425939.
81. Cui L., et al. Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-foot-and-mouth disease. PLoS ONE 2011, 6:e27071.
82. Buggele W.A., et al. Influenza A virus infection of human respiratory cells induces primary microRNA expression. J. Biol. Chem. 2012, 287:31027-31040.
83. Song H., et al. Microarray analysis of microRNA expression in peripheral blood mononuclear cells of critically ill patients with influenza A (H1N1). BMC Infect. Dis. 2013, 13:257.
84. Zhu Z., et al. Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans. Viruses 2014, 6:1525-1539.
85. Tambyah P.A., et al. microRNAs in circulation are altered in response to influenza A virus infection in humans. PLoS ONE 2013, 8:e76811.
86. Tacke F., et al. Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients. Crit. Care Med. 2014, 42:1096-1104.
87. Wang H.J., et al. Characterization and identification of novel serum microRNAs in sepsis patients with different outcomes. Shock 2013, 39:480-487.
88. Roderburg C., et al. Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis. PLoS ONE 2013, 8:e54612.
89. Ma Y., et al. Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis. PLoS ONE 2013, 8:e75918.
90. Wang H., et al. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. Clin. Chem. Lab. Med. 2012, 50:1423-1428.
91. Wang H., et al. Serum microRNA signatures identified by Solexa sequencing predict sepsis patients' mortality: a prospective observational study. PLoS ONE 2012, 7:e38885.
92. Ge Y., et al. Serum microRNA expression profile as a biomarker for the diagnosis of pertussis. Mol. Biol. Rep. 2013, 40:1325-1332.
93. Yi Z., et al. Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. PLoS ONE 2012, 7:e43184.
94. Kleinsteuber K., et al. Decreased expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4(+) T cells and peripheral blood from tuberculosis patients. PLoS ONE 2013, 8:e61609.
95. Miotto P., et al. miRNA signatures in Sera of patients with active pulmonary tuberculosis. PLoS ONE 2013, 8:e80149.
96. Qi Y., et al. Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infect. Dis. 2012, 12:384.
97. Mejias A., Ramilo O. Transcriptional profiling in infectious diseases: ready for prime time?. J. Infect. 2014, 68(Suppl. 1):S94-S99.
98. Li S., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 2014, 15:195-204.
99. Myers F.B., et al. A handheld point-of-care genomic diagnostic system. PLoS ONE 2013, 8:e70266.
100. Aderem A., et al. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. MBio 2011, 2:e00325-e410.
101. Kash J.C., et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006, 443:578-581.
102. Kobasa D., et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007, 445:319-323.
103. Cilloniz C., et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J. Virol. 2010, 84:7613-7624.
104. Cilloniz C., et al. Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog. 2009, 5:e1000604.
105. Baas T., et al. Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J. Virol. 2006, 80:10813-10828.
106. Ding M., et al. Gene expression in lung and basal forebrain during influenza infection in mice. Genes Brain Behav. 2008, 7:173-183.
107. Kash J.C., et al. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2011, 2. e00172-11.
108. Berry M.P., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
109. Kaforou M., et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med. 2013, 10:e1001538.
110. Anderson S.T., et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N. Engl. J. Med. 2014, 370:1712-1723.